Additional information
Active substance | Cagrilintide acetate |
---|---|
Formula | Not specified |
Side effects | Potential for gastrointestinal disturbances, injection site reactions, and nausea |
Effects | Promotes weight loss, reduces caloric intake, improves glycemic control |
Dosage (sports) | Not applicable as not typically used in sports settings |
Dosage (medical) | Typically administered as a subcutaneous injection, dosage varying depending on clinical trial phase and specific medical guidelines |
Half-life | Approximately 7 days |
Main action | Reduces appetite and enhances weight loss |
Substance class | Peptide analog |
Chemical name | Cagrilintide acetate |
Storage conditions | Store in a refrigerator, protect from light |
FORM | 1 vial x 10 mg |
Trade name | Not marketed under a specific trade name yet |
Blood pressure | Can potentially lower blood pressure due to weight loss effects |
Also known as | No alternative names reported |
Lab Test | Specific tests for monitoring levels not commonly used in clinical practice |
Hepatotoxicity | No significant hepatotoxic effects reported |
Water Retention | Minimal to none |
Use in sports | Not commonly used for sports enhancement |
Manufacturer | Dragon Pharma |
Reviews
There are no reviews yet.